Biomarin Pharmaceutical Inc: Highlights
Financial data in U.S. dollars
| Financial Highlights |
|---|
| Sales |
336.85 Mil |
| Income |
19.31 Mil |
| Net Profit Margin |
5.73% |
| Return on Equity |
7.13% |
| Debt/Equity Ratio |
1.64 |
|
| Revenue/Share |
3.12 |
| Earnings/Share |
0.14 |
| Book Value/Share |
3.02 |
| Dividend Rate |
0.00 |
| Payout Ratio |
0.00% |
|
| Revenue - Quarterly Results (in Millions) |
|---|
| | FY (12/09) | FY (12/08) | FY (12/07) |
|---|
| 1st Qtr | 74.0 | 60.4 | 22.8 |
| 2nd Qtr | 82.8 | 64.2 | 28.9 |
| 3rd Qtr | 80.8 | 72.6 | 25.0 |
| 4th Qtr | NA | 99.3 | 44.9 |
| Total | 237.6 | 296.5 | 121.6 |
| Earnings Per Share - Quarterly Results |
|---|
| | FY (12/09) | FY (12/08) | FY (12/07) |
|---|
| 1st Qtr | -$0.13 | $0.02 | -$0.10 |
| 2nd Qtr | $0.01 | $0.04 | -$0.04 |
| 3rd Qtr | $0.07 | $0.01 | -$0.05 |
| 4th Qtr | NA | $0.25 | $0.03 |
| Total | -$0.05 | $0.32 | -$0.16 |
| Qtr. over Qtr. EPS Growth Rate |
| FY (12/09) | FY (12/08) | FY (12/07) |
|---|
| 1st Qtr | NA | -33% | --- |
| 2nd Qtr | NA | 100% | 60% |
| 3rd Qtr | 600% | -75% | -25% |
| 4th Qtr | NA | 2,400% | NA |
| Yr. over Yr. EPS Growth Rate |
| FY (12/09) | FY (12/08) |
|---|
| 1st Qtr | NA | NA |
| 2nd Qtr | -75% | NA |
| 3rd Qtr | 600% | NA |
| 4th Qtr | NA | 733% |
advertisement
Recent News